A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

Until recently, the approved first-line treatment for metastatic RCC (mRCC) consisted of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor receptors (VEGFR) monotherapy. The landscape of first-line treatment has been transformed in the last few years with the advent o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiako Meyo, Manuela, Chen, Jeanne, Goldwasser, Francois, Hirsch, Laure, Huillard, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275425/
https://www.ncbi.nlm.nih.gov/pubmed/35837579
http://dx.doi.org/10.2147/TCRM.S263832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275425/
https://www.ncbi.nlm.nih.gov/pubmed/35837579
http://dx.doi.org/10.2147/TCRM.S263832

Ejemplares similares